Calliditas Therapeutics AB

Developing global, high-value products for patients with significant unmet medical needs in niche indications

Find out more about us

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Events

Calliditas shortlisted for the Capital Market Transaction of the Year at the European Mediscience Awards.

Press releases

Jul 3, 2019Calliditas has resolved on a directed share issue in the amount of 3.5 million shares, raising proceeds of approximately SEK 210 million
Jul 2, 2019Calliditas considers a directed share issue
Jun 10, 2019Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

All press releases

Interim report January 1 – March 31, 2019

On May 8, 2019 Calliditas Therapeutics published its business update for Interim report January 1 – March 31, 2019.

Read the report

Calendar

Aug 15, 2019Interim report for the period 1 January – 30 June 2019
Nov 14, 2019Interim report for the period 1 January – 30 September 2019
Feb 14, 2020Year-end report for the period 1 January – 31 December 2019